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Copyright © 2011 JCBN 2011 This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unre- stricted use, distribution, and reproduction in any medium, pro- vided the original work is properly cited. Although alcohol abuse is the most common cause of liver cirrho 
sis in the United States, the enhancing effects of alcohol on the
long term prognosis of hepatitis C virus (HCV) related liver cirrho 
sis has not been clarified. To investigate how alcohol abuse influ 
ences the prognosis of hepatitis virus related liver cirrhosis, we
studied 716 Japanese patients. Cumulative survival and hepatocel 
lular carcinoma (HCC) development rates were analyzed in alcohol
abusive, cirrhotic patients with or without hepatitis virus infec 
tion. Patients who abused alcohol were younger (p<0.0001) than
HCV infected, non abusive patients. The overall survival rate
among patients with alcoholic cirrhosis (Al group), HCV related
cirrhosis (HCV group), and HCV infected + alcoholic cirrhosis
(HCV + Al group), showed no significant differences, although the
10 year cumulative survival rate of Al group was the highest of
the three groups. The HCC development rate of Al group was the
lowest. In addition, alcohol abuse decreased the survival rates of
HCV group in the early stage with no HCC (p = 0.0028). In conclu 
sion, alcohol abuse might affect the progression of liver damage
in HCV infected patients with liver cirrhosis in the early stage,
although the influence of alcohol abuse on the long term progno 
sis seems to be rather small.
Key Words: prognosis of liver cirrhosis, alcoholic liver disease, 
hepatitis C virus, hepatocellular carcinoma
Introduction Alcohol abuse is a serious problem, in the United States and
Europe, which causes liver cirrhosis.(1,2) Alcohol liver disease
(ALD) is the cause of 40% of all liver cirrhosis in the United
States.(3) The relative risk for development of hepatocellular
carcinoma (HCC) between ALD and hepatitis C viruses (HCV)
infection has already been reported.(4) We previously reported that
alcohol and HCV infection together accelerate the development of
HCC.(5) Alcohol abuse may also affect the prognosis of HCV
infected patients with liver cirrhosis. However, the influence of
alcohol abuse on the long-term prognosis of HCV infected
patients with liver cirrhosis has not been clearly demonstrated.
In this study, we analyzed 716 Japanese cirrhotic patients and
determined differences in prognosis.
Materials and Methods
Patients. We retrospectively analyzed the clinical data of a
total of 716 patients with liver cirrhosis who were admitted to
Kanazawa Medical University Hospital (Ishikawa, Japan) from
1972 to 2007. The diagnosis of liver cirrhosis was mainly made by
histological evaluation of liver biopsy specimens and in 232 cases
it was confirmed by computed tomographic (CT) scans, ultra-
sonography, blood chemistry, and/or physical examinations. HCC
was diagnosed by histological examination, celiac angiography,
CT scans (enhanced arterial and portal venous phases) or ultra-
sonography.
Three etiological groups were made and 525 of the 716 cirrhotic
patients were placed in one of the following groups: alcohol (Al),
HCV infected (HCV) or HCV with Al (HCV + Al). The other 191
patients had etiology of liver cirrhosis unlike Al and HCV. Diag-
nosis of ALD was based on criteria of Takada et al.(6) That is, the
alcoholic patients have liver dysfunction with 80 g ethanol intake
per day for more than 5 years and the other causes of their liver
damage could be excluded. HCV infection status was diagnosed
when serum anti-HCV antibody and HCV RNA polymerase chain
reaction were positive.
We treated cirrhotic patients with ursodeoxycholic acid, if,
serum aspartate aminotransferase or alanine aminotransferase
levels were increased. When elevation of aminotransferase over
150 U/l was observed, we treated them with glycine intravenously.
If serum albumin levels were decreased under 3.5 g/dl, we treated
them with branched-chain amino acid orally. When the patient had
a hepatic encephalopathy, we treated them with lactulose and
cathartics and/or kanamycin orally and/or branched-chain amino
acid intravenously. When the patients had an ascites, we treated
them with furosemide and spironolactone. If these patients had a
decreased level of serum albumin level under 2.5 g/dl, we treated
them with albumin preparations intravenously. There were no
HCV related cirrhotic patients who were treated with interferon
based antiviral treatment.
Clinical characteristics of the patients. In each group, we
retrieved their sex, age at diagnosis and the occurrence rate of
HCC from medical records, and prepared summary statistics.
Long term prognosis and HCC development. The cumula-
tive survival rate of each group was calculated. Furthermore, the
cumulative rate of HCC development was calculated for 413 (out
of 525) non-HCC patients at diagnosis.
Statistical analysis. Data were expressed as means ± standard
deviation (SD). The Mann-Whitney U test was used for statistical
analysis for the age at diagnosis in each group. Cumulative sur-
vival rates and the rates of HCC development were calculated with
the Kaplan-Meier method. The statistical analysis for the cumula-
tive 10-year and overall survival rates including both HCC and
non-HCC patients were evaluated with the Log-rank method. The
statistical analysis for the cumulative 5-year and overall survival
rates in non-HCC patients and cumulative rates of HCC develop-
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ment were also evaluated with the Log-rank method. A p value
<0.05 was considered significant.
Results
Clinical characteristics of patients with liver cirrhosis.
The characteristics in each group are shown in Table 1. There were
a total of 525 patients and the male to female ratio was 2.3:1, indi-
cating that the male gender has a predisposition to liver cirrhosis.
Approximately 91% of patients in Al group were male subjects.
The male to female ratio was 1:1 in HCV group. Almost all cir-
rhotic patients with HCC had HCV infection. The patients in Al
and HCV + Al groups were significantly younger than those in
HCV group (p<0.0001).
Prognosis of liver cirrhosis caused by alcohol abuse with
or without virus related liver cirrhosis. The 3-year survival
rates of Al group, HCV group and HCV + Al group were 77.8%,
71.6% and 66.8%, respectively. The 5-year survival rates were
66.3%, 55.6% and 57.4%, respectively. The 10-year survival rates
were 50.7%, 30.7% and 35.3%, respectively. The cumulative
survival rate of Al group was higher than that of HCV group
(p = 0.013) or HCV + Al group (p = 0.075) during the 10 years
from the diagnosis of cirrhosis. The 20-year survival rates were
0% in all groups. The cumulative overall survival rate in Al group
was higher than that of HCV + Al group0000 (p = 0.093) or HCV
group (p = 0.071).
In the total 413 non-HCC patients at the diagnosis of liver cir-
rhosis, 9 of 157 patients in Al (5.7%), 11 of 51 patients in
HCV + Al (21.6%) and 39 of 205 patients in HCV (19.0%) had
HCC for 20 years. The cumulative HCC development in Al, HCV
and HCV + Al groups are shown in Fig. 1. The 10-year rates of
HCC development in Al, HCV and HCV + Al were 13.4%, 46.9%
and 39.3%, respectively. The cumulative rate of HCC develop-
ment in Al group was significantly lower than that in HCV group
(p = 0.0065), and lower than that in HCV + Al group, but not sig-
nificantly (p = 0.063).
The cumulative survival rates of patients who did not develop
HCC, 148 patients in Al group, 40 patients in HCV + Al group and
166 patients in HCV group, were monitored. Those of Al, HCV
and HCV + Al groups are shown in Fig. 2. The 5-year survival
rates of Al, HCV and HCV + Al were 73.2%, 74.5% and 66.7%,
respectively. The 10-year survival rates were 57.5%, 46.5% and
50.5%, respectively. Regarding the overall survival rate, there
were no significant differences among the HCV + Al, HCV and Al
groups. The 5-year cumulative survival rate of HCV + Al group
was lower than that of HCV group (p = 0.0028) or Al group
(p = 0.089). In addition, HCV + Al group had the worst survival
rate among the 3 groups, at 8.2 years.
The survival rate of patients who did not develop HCC was
higher than that of patients who developed HCC over the esti-
mated period.
Discussion
In this study, no significant differences of the 20-year
cumulative survival rate among the Al, HCV and HCV + Al
groups were seen, although the 10-year cumulative survival rate of
Al group was higher than that of HCV or HCV + Al group. In ad-
dition, alcohol abuse decreased the cumulative survival rates in
early-stage of HCV-related liver cirrhotic patients with no HCC at
the diagnosis of liver cirrhosis.
HCC development is considered to be an important factor of
mortality in patients with liver cirrhosis (7). In our study, the rate of
HCC development in Al group was lower than that in HCV or
HCV + Al group. Therefore, the 10-year survival rate of Al group
might be higher than that of HCV or HCV + Al group. However,
no significant difference of the 20-year cumulative survival rate
was seen among HCV, Al and HCV + Al groups, because the
failure of liver function as well as HCC development might influ-
ence the more long-term survival.
At the diagnosis of cirrhosis, the patients in HCV + Al group
were significantly younger than those in HCV group. Therefore,
alcohol is considered to quicken the progression of HCV-related
liver cirrhosis. However, the influence of alcohol on the long-term
prognosis of HCV-related liver cirrhosis is considered to be negli-
gible. We could not analyze the reason for this, because the
number of patients in the late stage of liver cirrhosis decreased
over time.
Our previous and the other studies have found that chronic alco-
holic patients with HCV infection have more impaired liver func-
tion than without HCV infection.(8,9) However, the mechanism for
Table 1. Clinical characteristics of the patients with liver cirrhosis
1972–2007 years. *: standard deviation, #: p<0.0001, HCC: hepatocellular








Al 172 (24.0) 157 15 56.0 ± 10.5 24 (14.0)
HCV + Al 67 (9.4) 62 5 58.0 ± 10.0 27 (40.3)
HCV 286 (39.9) 145 141 65.0 ± 11.1 120 (42.0)
Total 525 364 161 61.0 ± 11.4 171 (32.6)
Fig. 1. Cumulative rates of HCC development in patients with liver
cirrhosis. Al group had a lower cumulative rate of HCC development
than HCV + Al or HCV group (p = 0.06 or 0.006, respectively).
Fig. 2. Cumulative survival rates of cirrhotic patients who did not
develop HCC. HCV + Al group had the worst survival rate at 8.2 years.
The 10 year cumulative survival rate of HCV + Al group is 16.7% lower,
and of HCV group is 20.8% lower than that of Al group. J. Clin. Biochem. Nutr. | March 2011 | vol. 48 | no. 2 | 169
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the enhancing effects of alcohol on the prognosis of HCV-related
liver cirrhosis is still not clear. We previously reported in 39 pa-
tients with alcoholic liver damage that HCV infected patients had
a higher cumulative rate of HCC development and a lower
cumulative survival rate than non-HCV infected patients.(9) The
present study also showed similar results based on a larger number
of patients than the previous study.
We have reported that the development of HCV related-HCC
may be enhanced by alcohol abuse.(5) However, in the present
study, there was no significant difference of the cumulative rate of
HCC development between HCV and HCV + Al groups. The pre-
vious study was a multiple logistic-regression analysis conducted
with a larger number of patients in five different hospitals.(5) These
differences may be related to the differences in statistical signifi-
cance.
In this study, alcohol abuse might affect the decreased survival
rates in early-stage of HCV-infected liver cirrhotic patients with
no HCC at the diagnosis of liver cirrhosis, although this effect on
the overall prognosis of HCV infected cirrhotic patients seems to
be rather small. The peroxidation of lipids and production of reac-
tive oxygen species (ROS) are major factors in alcoholic liver
damage.(10) Recently, it was clarified that they are also related to
the pathogenesis of chronic type C hepatitis. Moriya et al.(11,12) re-
ported that the HCV core protein induced hepatic steatosis and
HCC in transgenic mice. Otani et al.(13) reported that mitochon-
drial ROS production in Huh-7 cell was up-regulated by ex-
pressing HCV core protein and the more production was seen by
ethanol-load. In addition, it was also reported that alcohol depleted
the mitochondrial reduced glutathione, which exacerbates depo-
larization and cell death. Consequently, the degradation of lipids
and production of ROS are considered to be involved in the
damage of hepatocytes in HCV infected patients with alcohol
abuse. In fact, Ye et al.(14) reported in cultured hepatoma cells that
HCV RNA replication was disrupted by treatment with lovastatin,
an inhibitor of 3-hydroxy-3-methyglutaryl CoA reductase. Fur-
thermore, Emerit et al.(15) reported that Cu/Zn superoxide dis-
mutase reduced the expression of transforming growth factor-
beta1 (TGF-β1) in transgenic mice over-expressed the HCV core
protein. Further studies are required to evaluate the effects of
antidyslipidemic and/or antioxidant therapy in HCV-related liver
cirrhosis.
In the United States, alcohol is the most common cause of liver
disease.(3) Armstrong et al.(16) reported that the prevalence of HCV
infection has remained broadly constant, with 3.2 million people
infected with HCV, and the number of patients with infection for
over 20 years is expected to peak in 2015. Therefore, treatment for
alcoholic patients with HCV infection will become a major
problem.
Conclusions
We concluded that alcohol abuse might affect the progression of
liver damage in early stage cirrhotic patients with HCV infection,
although the influence of alcohol abuse on the long term prognosis
of cirrhotic patients with HCV infection seems to be rather small.
Therefore, cirrhotic patients with HCV infection should strictly
abstain from alcohol.
Abbreviations
ALD alcohol liver disease
HCC hepatocellular carcinoma




TGF-β1 transforming growth factor-beta1
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